Vesica Health's AssureMDx provides physicians and hematuria patients with a noninvasive test to improve the early detection and treatment of bladder cancer.

Dr. Porten started her academic journey by earning her undergraduate, doctoral, and public health degrees from Northwestern University. During medical school, she was inducted into the Alpha …

Bringing Clarity to Clinical Decisions Early detection remains essential to improving outcomes for bladder cancer patients.

Christopher is an established leader in molecular diagnostics for urology and oncology. He has led team initiatives that successfully established operations, launched innovative products, delivered clinical …

Dr. Lee is Professor and Chair of the Department of Urology at The Ohio State University where she holds the Dorothy M. Davis Endowed Chair in Cancer Research. She is also the Vice President of …

Vesica Health's AssureMDx provides physicians and hematuria patients with a noninvasive test to improve the early detection and treatment of bladder cancer.

Dr. Steinberg is a recognized expert in translational bladder cancer research and innovative clinical trials. He is a pioneer in the use of blue light cystoscopy to detect and remove early-stage bladder …

Dr. Lotan is the co-chair of the Harold C. Simmons Comprehensive Cancer Center disease-oriented team for urologic cancers. He is a member of UT Southwestern’s Clinical Research Planning Group …

Peter Black, MD, FACS, FRCSC Scientific Advisory Board, Vesica Health

Dr. Daneshmand serves on the AUA Guideline panel for non-muscle invasive bladder cancer, as well as the AUA Guidelines panel for Testicular cancer. He currently serves as the chair of bladder section of …